Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not meet the main goal. ...

Exhibit 99.1 Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE Based on the encouraging trends seen in ESSENCE, the substantial real-world evidence, and the positive safety profile of AMONDYS 45 and VYONDYS 53, Sarepta intends to schedule a meeting with the U.S. Food and Drug Administration (FDA) to discuss the possibility of converting from accelerated to traditional approval. Sarepta continues to a ...

Core Insights - Kalaris Therapeutics has appointed Matthew Gall as Chief Financial Officer to enhance its leadership team and support the company's growth as it advances its clinical studies [1][2] - The company is focused on developing treatments for retinal diseases, particularly neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) [3] Company Overview - Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to addressing major unmet medical needs in retinal diseases [3] - The company was founded by Dr. Napoleone Ferrara, known for his pioneering research in anti-VEGF therapy [3] Leadership and Experience - Matthew Gall brings extensive experience from previous roles at iTeos Therapeutics, Sarepta Therapeutics, Celgene Corporation, and Gilead Sciences, focusing on financial operations and business development [2] - His appointment is expected to bolster Kalaris' strategic direction and support its clinical development efforts [2]

Summary of Avidity Biosciences FY Conference Call Industry Overview - The focus of the conference was on muscular dystrophies, particularly Duchenne Muscular Dystrophy (DMD) and Facioscapulohumeral Muscular Dystrophy (FSHD) [1][24] - DMD is a multibillion-dollar market projected to grow to $3 billion by 2033 [1] - Other muscular dystrophies like DM1 and FSHD currently lack approved therapies, but promising treatments are in development [1] Key Points on DMD Treatments - Current DMD treatments include first-generation PMO exon-skipping therapies, new gene therapies, and steroids, but significant unmet needs remain, especially for non-ambulatory patients [2][3] - The FDA's approval of the first PMO exon-skipping therapy is seen as a watershed moment that opened investment in the DMD space [3][4] - The approval set a low regulatory bar, leading to increased investment and development of new therapies [3][5] - New technologies, such as Antibody Oligonucleotide Conjugates (AOCs), are being developed to improve dystrophin production and functional benefits [9][10] Clinical Data and Efficacy - AOCs have shown promising results, with 40% exon skipping and a 25% increase in dystrophin levels [10][11] - Creatine kinase (CK) levels, a measure of muscle damage, have returned to normal for many patients, indicating functional improvement [11][14] - The FDA's low bar for approval has allowed for a variety of therapies to enter the market, but safety and efficacy remain critical [16][19] Gene Therapy Insights - Sarepta Therapeutics' Elevidys gene therapy faced scrutiny but initially showed strong uptake due to the unmet need in DMD [16] - Avidity's approach focuses on optimizing the gene therapy construct and manufacturing processes to improve safety and efficacy [18][19] - The company has developed a microdystrophin that closely resembles natural dystrophin, aiming for higher expression and longer half-life [17][18] FSHD Developments - FSHD is characterized by the aberrant expression of the DUX4 transcription factor, which is toxic to muscle cells [26][27] - Avidity is using AOC technology to deliver silencing RNA to inhibit DUX4 expression, showing early signs of clinical benefit [27][30] - The identification of a circulating biomarker (C-DUX) for DUX4 may facilitate accelerated approval processes [29][32] Market Dynamics and Future Outlook - The DMD market is expected to see multiple effective therapies, with opportunities for various players due to the large unmet need [41][42] - The potential for combination therapies is highlighted, with patients and physicians open to using multiple modalities for better outcomes [47][48] - The FDA's accelerated approval pathway is anticipated to remain in place to encourage ongoing innovation in the muscular dystrophy space [49] Conclusion - The conference highlighted the significant advancements in genetic medicine for muscular dystrophies, the importance of regulatory pathways, and the potential for new therapies to address unmet needs in DMD and FSHD [1][41][49]

Core Insights - Sarepta Therapeutics, Inc. (NASDAQ: SRPT) has faced scrutiny due to disappointing results from recent clinical trials, impacting its stock price significantly [1] - The company operates in the biotechnology sector, focusing on innovative drug development through unique mechanisms of action and first-in-class therapies [1] Company Overview - Sarepta Therapeutics is involved in developing therapies that aim to reshape treatment paradigms in the biotech industry [1] - The company has a pipeline that includes both early clinical candidates and commercial-stage products, indicating a diverse range of development stages [1] Market Analysis - The biotechnology sector is characterized by the potential for breakthrough science to yield substantial returns, but it also requires careful scrutiny of clinical trial designs and competitive landscapes [1] - The analysis emphasizes the importance of evaluating the science behind drug candidates and understanding the market opportunities available [1]

Core Insights - Sarepta Therapeutics, Inc. (NASDAQ: SRPT) has faced scrutiny due to disappointing results from recent clinical trials, impacting its stock price significantly [1] Company Overview - Sarepta Therapeutics is focused on biotechnology, particularly in developing innovative therapies with unique mechanisms of action and first-in-class treatments [1] - The company aims to reshape treatment paradigms through its platform technologies [1] Investment Analysis - The analysis emphasizes the importance of evaluating the scientific basis of drug candidates, the competitive landscape, clinical trial design, and potential market opportunities [1] - The biotech sector is characterized by the potential for breakthrough science to yield substantial returns, necessitating careful scrutiny of investments [1]

Core Insights - Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock is experiencing an upward trend without any specific news to explain the increase [1] - The company is set to present data on its gene therapy, delandistrogene moxeparvovec, for Duchenne muscular dystrophy (DMD) this week [1] Group 1: Clinical Developments - Sarepta will present results from multiple studies related to the delandistrogene moxeparvovec clinical development program, including a real-world evidence study on pulmonary function in advanced-stage DMD patients treated with casimersen [2] - Independent studies on delandistrogene moxeparvovec will also be presented, including an abstract on the use of sirolimus prophylaxis to mitigate potential acute liver injury in patients receiving the therapy [3] - Results from the EMERGENE phase 3 study on SGCB expression and safety following bidridistrogene xeboparvovec treatment in LGMD2E/R4 patients will be shared [4] Group 2: Regulatory Updates - The FDA had previously requested Sarepta to halt shipments of its drug after a reported death in a young patient in Brazil, but reversed its decision allowing the company to resume shipments for certain patients [4][5] Group 3: Stock Performance - As of the latest update, Sarepta Therapeutics stock is trading at $23.12, with a premarket increase of 4.67% to $24.20 [7][8]

Group 1 - The article highlights the challenges faced by Sarepta Therapeutics, Inc. in 2025, indicating it has been a particularly difficult year for the company [1] - The investing group Haggerston BioHealth offers insights for both novice and experienced biotech investors, including catalysts to watch and buy/sell ratings [2] - The group provides detailed financial analyses, including product sales forecasts and integrated financial statements for major pharmaceutical companies [2]

Core Insights - Sarepta Therapeutics, Inc. is recognized as a leader in precision genetic medicine for rare diseases [1] - The company will present at the 30th Annual Congress of the World Muscle Society (WMS) 2025 Congress scheduled for October 7-11, 2025, in Vienna, Austria [1] - Presentations will include results from multiple studies related to the delandistrogene moxeparvovec clinical development program, as well as a real-world evidence study focusing on pulmonary function in advanced-stage patients [1]

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of Sarepta Therapeutics, Inc. related to the misrepresentation of safety risks associated with the ELEVIDYS treatment [1] Group 1: Allegations Against Sarepta Therapeutics - Insiders at Sarepta Therapeutics allegedly caused the company to misrepresent or fail to disclose significant safety risks posed by the ELEVIDYS treatment [1] - The trial regimes and protocols for ELEVIDYS reportedly failed to detect severe side effects, leading to concerns about patient safety [1] - The severity of adverse events from ELEVIDYS treatment may result in the company halting recruitment and dosing in trials, attracting regulatory scrutiny, and increasing risks around the therapy's approvals [1] - Insiders are accused of materially misleading stakeholders and lacking a reasonable basis for their positive statements regarding ELEVIDYS [1]